Business Context and Reporting Period
This Form 6-K filing by Sanofi-Aventis, dated August 24, 2004, announces a mandatory publication pursuant to the German Securities Acquisition and Takeover Act (WpUG). The report details the acquisition of majority control over Aventis on August 20, 2004, which resulted in Sanofi-Aventis gaining indirect control over Aventis' subsidiary, Hoechst Aktiengesellschaft.
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and regulatory compliance regarding a change in control.
- Shareholding: Aventis holds 548,451,852 shares of Hoechst Aktiengesellschaft, representing 98.09% of the registered share capital and voting rights.
- Control Transfer: Following the acquisition of Aventis, these voting rights are attributed to Sanofi-Aventis.
Material Changes
The primary material change is the shift in corporate control structure:
- Sanofi-Aventis acquired majority participation in Aventis on August 20, 2004.
- Consequently, Sanofi-Aventis, along with Total, L'Oreal, Tethys SAS, the Bettencourt family members, and Nestle S.A., gained indirect control over Hoechst Aktiengesellschaft.
- This change triggers a mandatory offer obligation to the remaining outside shareholders of Hoechst Aktiengesellschaft under Section 35 of the WpUG.
Guidance, Outlook, and Risks
Outlook and Actions: Sanofi-Aventis intends to make a mandatory offer to outside shareholders of Hoechst Aktiengesellschaft following approval by the German Federal Financial Supervisory Authority (BAFIN). The offer document will be published on the company's website and via public announcement. The company reserves the right to purchase shares outside the mandatory offer, subject to applicable securities laws.
Risks and Contingencies: The filing contains forward-looking statements regarding the offer process and future actions. These statements are subject to uncertainties and changes in circumstances outside the company's control. Actual events may differ materially from expectations. The company does not undertake an obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the publication of the official offer document on http://www.sanofi-aventis.com following BAFIN approval.
- Confirm the specific terms, price, and timeline of the mandatory offer to Hoechst Aktiengesellschaft shareholders.
- Monitor for any share purchases made by Sanofi-Aventis outside the mandatory offer framework.
- Review subsequent filings for financial integration details of Aventis and Hoechst into Sanofi-Aventis.